Xi'an Prius Biological Engineering Co.,Ltd
Address:Room 0836, Euro-Asia International Building A, Ouya avenue, Xi'an, Shaanxi Province, China
The first human clinical trial targeting the beta-nicotinamide mononucleotide (nmn) / NAD + transcriptome in China was approved by ethics review at Shanghai Changzheng Hospital in February 2022.
It is the first human clinical trial of NMN conducted in a high-ranking hospital in China, which marks the beginning of a serious clinical evidence-based phase in our study targeting nicotinamide mononucleotide (NMN). This experiment, which aims to investigate the effects on the human transcriptome level via the nmn-nad + signaling pathway in healthy people after the administration of NMN, is the first worldwide effort to quantitatively address a whole new and characteristic quantitative biomarker of human aging and is of great significance.
This trial will be conducted in two phases. The first phase targeted different age groups for this innovative biomarker benchmark level determination and analysis, aiming to establish a foundational understanding of this biomarker in humans; The second phase will be aimed at conducting randomized double-blind controlled trials before and after NMN administration, aiming to analyze the effects of beta-nicotinamide mononucleotide (nmn) on this biomarker in humans, as well as on the transcriptome level such as senescence-related gene regulation, cell cycle regulation, and disease-related gene size.
99.9% pure NMN starting material was used for the test. Academia promotes the development of NMN-related basic research, provides a solid and reliable scientific basis, and enjoys the results of cutting-edge science and technology. In addition, this trial is able to help beta-nicotinamide mononucleotide (nmn) suppliers better understand the variability in demand for NMN among different populations and, in turn, provide consumers with an individualized NMN regimen.